Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$7.87 - $15.15 $54,987 - $105,853
-6,987 Closed
0 $0
Q4 2021

Jun 21, 2023

BUY
$13.09 - $18.77 $91,459 - $131,145
6,987 New
6,987 $111,000
Q3 2021

Jun 21, 2023

BUY
$13.03 - $19.51 $91,040 - $136,316
6,987 New
6,987 $128,000
Q2 2021

Jun 21, 2023

BUY
$12.22 - $15.79 $85,381 - $110,324
6,987 New
6,987 $97,000
Q2 2021

Mar 30, 2023

BUY
$12.22 - $15.79 $22,020 - $28,453
1,802 Added 34.75%
6,987 $97,000
Q2 2021

Aug 16, 2021

BUY
$12.22 - $15.79 $85,320 - $110,245
6,982 Added 139640.0%
6,987 $98,000
Q1 2021

Jun 26, 2023

BUY
$13.23 - $21.48 $68,597 - $111,373
5,185 New
5,185 $76.3 Million
Q1 2021

Mar 30, 2023

SELL
$13.23 - $21.48 $18,588 - $30,179
-1,405 Reduced 21.32%
5,185 $76,000
Q1 2021

May 14, 2021

SELL
$13.23 - $21.48 $87,119 - $141,445
-6,585 Reduced 99.92%
5 $76,000
Q4 2020

Jun 22, 2023

BUY
$11.65 - $22.07 $76,773 - $145,441
6,590 New
6,590 $127,000
Q4 2020

Mar 30, 2023

BUY
$11.65 - $22.07 $15,878 - $30,081
1,363 Added 26.08%
6,590 $127,000
Q4 2020

Feb 16, 2021

BUY
$11.65 - $22.07 $76,773 - $145,441
6,590 New
6,590 $128,000
Q3 2020

Nov 13, 2020

SELL
$8.96 - $14.12 $46,833 - $73,805
-5,227 Closed
0 $0
Q2 2020

Jun 26, 2023

BUY
$7.27 - $14.18 $38,000 - $74,118
5,227 New
5,227 $70,000
Q2 2020

Mar 30, 2023

BUY
$7.27 - $14.18 $38,000 - $74,118
5,227 New
5,227 $70,000
Q2 2020

Aug 14, 2020

BUY
$7.27 - $14.18 $38,000 - $74,118
5,227 New
5,227 $71,000

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $33.3M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.